Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells by Pifano, Marina et al.
January 2017 | Volume 7 | Article 111
Original research
published: 30 January 2017
doi: 10.3389/fonc.2017.00011
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Giovanni Li Volti, 
University of Catania, Italy
Reviewed by: 
Daniel Christian Hoessli, 
International Center for Chemical and 
Biological Sciences (ICCBS), 
Switzerland  
Giorgio I. Russo, 
University of Catania, Italy
*Correspondence:
Giselle V. Ripoll 
gripoll@gmail.com
Specialty section: 
This article was submitted to 
Molecular and Cellular Oncology, 






Pifano M, Garona J, Capobianco CS, 
Gonzalez N, Alonso DF and Ripoll GV 
(2017) Peptide Agonists of 
Vasopressin V2 Receptor Reduce 
Expression of Neuroendocrine 
Markers and Tumor Growth in Human 
Lung and Prostate Tumor Cells. 
Front. Oncol. 7:11. 
doi: 10.3389/fonc.2017.00011
Peptide agonists of Vasopressin V2 
receptor reduce expression of 
neuroendocrine Markers and Tumor 
growth in human lung and Prostate 
Tumor cells
Marina Pifano, Juan Garona, Carla S. Capobianco, Nazareno Gonzalez, Daniel F. Alonso 
and Giselle V. Ripoll*
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Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that 
express neuropeptides as synaptophysin, chromogranin A (CgA), and specific neuronal 
enolase (NSE), among others. Vasopressin (AVP) is a neuropeptide with an endocrine, 
paracrine, and autocrine effect in normal and pathological tissues. AVP receptors are 
present in human lung, breast, pancreatic, colorectal, and gastrointestinal tumors. While 
AVP V1 receptors are associated with stimulation of cellular proliferation, AVP V2 recep-
tor (V2r) is related to antiproliferative effects. Desmopressin (dDAVP) is a synthetic analog 
of AVP that acts as a selective agonist for the V2r, which shows antitumor properties 
in breast and colorectal cancer models. Recently, we developed a derivative of dDAVP 
named [V4Q5]dDAVP, which presents higher antitumor effects in a breast cancer model 
compared to the parental compound. The goal of present work was to explore the 
antitumor properties of the V2r agonist dDAVP and its novel analog [V4Q5]dDAVP on 
aggressive human lung (NCI-H82) and prostate cancer (PC-3) cell lines with neuroen-
docrine (NE) characteristics. We study the presence of specific NE markers (CgA and 
NSE) and V2r expression in NCI-H82 and PC-3. Both cell lines express high levels of 
NE markers NSE and CgA but then incubation with dDAVP diminished expression levels 
of both markers. DDAVP and [V4Q5]dDAVP significantly reduced proliferation, doubling 
time, and migration in both tumor cell cultures. [V4Q5]dDAVP analog showed a higher 
cytostatic effect than dDAVP, on cellular proliferation in the NCI-H82 cell line. Silencing 
of V2r using small interfering RNA significantly attenuated the inhibitory effects of [V4Q5]
dDAVP on NCI-H82 cell proliferation. We, preliminarily, explored the in  vivo effect of 
dDAVP and [V4Q5]dDAVP on NCI-H82 small cell lung cancer xenografts. Treated tumors 
(0.3 μg kg−1, thrice a week) grew slower in comparison to vehicle-treated animals. In 
this work, we demonstrated that the specific agonists of V2r, dDAVP, and [V4Q5]dDAVP 
displays antitumor capacity on different human models of lung and prostate cancers 
with NE features, showing their potential therapeutic benefits in the treatment of these 
aggressive tumors.
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inTrODUcTiOn
Neuroendocrine tumors (NETs) comprise a diverse group of 
malignancies that present a broad range of morphological, 
functional, and behavioral characteristics. The concept of neu-
roendocrine (NE) differentiation can be defıned as the secretion 
of bioactive substances by the neoplastic cells (1).
Neuroendocrine tumors growth is mainly regulated by auto-
crine and paracrine signaling through neuropeptides, peptide 
hormones, and bioamines with defined physiologic actions, and 
it has been widely reported in lung, gastric, colorectal, pancreatic, 
and prostatic cancer (2, 3). These signaling pathways depend on 
the expression of specific receptors on tumor cells. Among others, 
proteins expressed by these tumors are the synaptophysin, the 
chromogranin A (CgA), and the specific neuronal enolase (NSE) 
(4, 5). CgA is the most widely used biomarker for detecting NE 
differentiation in prostate cancer either at tissue level or in general 
circulation (6). NSE is currently the most reliable tumor marker 
in diagnosis, prognosis, and follow-up of small cell lung cancer 
(SCLC) (7–10).
Somastostatin (SST) is a neuropeptide with paracrine activity 
secreted by intestinal, lung, pancreas, and different nerve cells. It 
acts as a strong secretion inhibitor of several hormones as insulin, 
gastrin, and some growth factors. It also inhibits the proliferation 
of both normal and tumor cells. Its biological activity is exerted 
through binding to five different G-protein-coupled recep-
tors (GPCRs) (11). Several analogs of somatostatin have been 
developed showing a potent biological activity with an enhanced 
stability in comparison to the parental peptide. It has been 
demonstrated that somatostatin and its analogs display antian-
giogenic and antiproliferative activity on tumor cells both in vitro 
and in vivo, highlighting that some neuropeptides and specially 
its synthetic derivatives could be potentially used as antitumor 
agents. In particular, SST analogs (SSA) are used frequently to 
control hormone-related symptoms in NE cancer patients while 
their anti-neoplastic activity seems to result prevalently in tumor 
stabilization (12).
Vasopressin (AVP also called antidiuretic hormone) is a neu-
ropeptide hormone synthesized primarily in the hypothalamus. 
Mainly, it has an endocrine effect but it is also secreted locally 
by many normal and pathological tissues exerting autocrine 
and paracrine activities (13). The effects of AVP are mediated 
by three GPCRs. These receptors are AVP type 1 receptor (V1ar, 
V1br also called V3r) and AVP type 2 receptor (V2r) and have 
numerous actions centrally and in the periphery (14, 15). The 
V1ar is typically expressed in vascular smooth muscle cells, where 
it mediates smooth muscle contraction and is also present in 
brain, adrenal cortex, adipose tissue, and hepatocytes. The V1br is 
mainly expressed in the anterior pituitary gland, adrenal medulla, 
islet cells of Langerhans, and white adipose tissue regulating the 
hypothalamic–pituitary–adrenal axis. V2r is expressed in the 
collecting ducts of the kidney and in alveolar vascular endothe-
lium epithelial cells, stimulating water absorption and release of 
hemostatic factors from micro vasculature (16).
Interestingly, there is evidence of the expression of AVP and 
their receptors in SCLC (17, 18), breast (19, 20), pancreatic 
and colorectal cancer, and human gastrointestinal tumors (1). 
Moreover, syndrome of inappropriate antidiuretic hormone 
secretion was reported in patients with prostate cancer and SCLC 
(21, 22).
While V1 receptors are associated with the stimulation of cel-
lular proliferation, V2r is related to antiproliferative effects (23). 
Desmopressin (dDAVP) is a synthetic peptide analog of AVP that 
acts as a selective agonist for the V2r. DDAVP differs from AVP by 
deamination of cystein in position 1, which prolongs its half-life; 
and substitution of l-arginine by d-arginine in position 8, which 
reduces the pressor effect and confers selectivity for V2r (24).
In our laboratory, we reported for the first time that dDAVP 
inhibits the dissemination of aggressive breast cancer cells (25) 
and colon carcinoma cells (26). We, further, demonstrated that 
peri-operative dDAVP treatment dramatically reduces lymph 
node and lung metastasis in a mouse model of mammary tumor 
manipulation and surgical excision (27).
Besides its antimetastatic properties, dDAVP has cytostatic 
properties and induces a tumor-mediated production of angio-
statin, a potent antiangiogenic effector (28, 29). Thereby dDAVP 
seems to induce a dual, angiostatic and antimetastatic, effect, 
disrupting the crosstalk of cancer cells and endothelial cells dur-
ing tumor progression (30).
Desmopressin was rationally modified in our laboratory 
to improve its biological activity. Parental peptide dDAVP was 
substituted in positions 4 and 5, and the novel analog [V4Q5]
dDAVP ([4-valine 5-glutamine] desmopressin) was synthesized 
and evaluated. Amino acid positions 4 and 5 belong to the con-
formational peptide loop which has a key role in ligand–receptor 
interaction and antitumor activity (31). [V4Q5]dDAVP exhibited 
a significantly higher cytostatic effect against breast cancer cells 
compared to the parental compound, inhibited angiogenesis in 
endothelial cell cultures, and also reduced tumor growth and 
angiogenesis in aggressive human breast cancer xenograft (32). 
Additionally, [V4Q5]dDAVP, in combination with cytotoxic 
agents, resulted in a cooperative inhibition of breast cancer 
growth and metastatic progression in comparison to single-agent 
therapy (33).
Considering the evidence that supports the autocrine and par-
acrine involvement of neuropeptides in the regulation of tumor 
growth in cancers, such as lung and prostate, the present work 
explores the antitumor properties of the V2r agonist dDAVP and 




Human SCLC cell line NCI-H82 (HTB-175), human non-small 
lung cancer cell line NCI-H125 (CRL-5801), and human prostate 
adenocarcinoma cell line PC-3 (CRL-1435) were obtained from 
the American Type Culture Collection. Tumor cells were grown 
in RPMI-1640 medium (Gibco, Rockville, MD, USA) supple-
mented with 10% fetal bovine serum (FBS), 2 mg ml−1 glutamine, 
and 80 μg ml−1 gentamycin as floating aggregates or monolayer 
culture, at 37°C in a humidified atmosphere of 5% CO2. Cells were 
harvested using a trypsin and EDTA solution (Gibco, Rockville, 
MD, USA) diluted in phosphate-buffered saline (PBS).
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Peptide compounds
Desmopressin and its analog [V4Q5]dDAVP were purchased 
from American Peptide Company Inc. (CA, USA, current 
BACHEM).
immunofluorescence Detection of V2r
V2r expression was evaluated by immunofluorescence as 
described elsewhere (29). Briefly, NCI-H125 and PC-3 cancer 
cells were seeded on glass coverslips and fixed with 4% para-
formaldehyde solution in PBS. NCI-H82 cells were subjected to 
centrifugation at 3,800  ×  g for 10  min. The supernatant fluids 
were drained off and cells were fixed with 4% paraformaldehyde 
solution in PBS. After incubation with blocking agent, cells 
were incubated with an anti-V2r primary antibody for 1  h 
at 37°C (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Receptor-bound antibodies were detected with a secondary 
FITC-conjugated goat anti-rabbit IgG (Chemicon International, 
Temecula, CA, USA) and nuclei were labeled with DAPI using the 
Vectashield fluorescent mounting medium (Vector Laboratories, 
Peterborough, UK). Samples were examined using a TE-2000 
fluorescence microscope (Nikon Inc., Tokyo, Japan). Cultures of 
MDA-MB-231 human breast carcinoma cells were used as a posi-
tive control of V2r expression (32). Negative controls consisted of 
omission of the primary antibody.
Quantitative rT-Pcr (qrT-Pcr)
Total RNA of NCI-H82, NCI-H125, and PC-3 treated or not 
with dDAVP 1,000  nM overnight (ON) was purified from 
1  ×  106 cells with Trizol according to the manufacturer’s 
protocol. RNA was reverse transcribed with SuperScript III 
first-Strand (Thermo Fisher Scientific Inc., USA) according 
to the manufacturer’s protocol. The following specific for-
ward and reverse primers were used as described elsewhere 
(34): for NSE, 5-GAGACAAACAGCGTTACTTAG-30 and 
50-AGCTGCCCCTGCCTTAC-3; for CgA, 5-GCGGTGGAA 
GAGCCATCAT-3 and 5-TCTGTGGCTTCACCACTTTTC 
TC-3; and for glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), 5-CATGGGTGTGAACCATGAGA-3 and 5-CAG 
TGATGGCATGGACTGTG-3 (35).
Quantitative RT-PCR was performed using SYBR Green PCR 
Master Mix (Thermo Fisher Scientific Inc., USA) and StepOne 
Real-Time PCR System (Applied Biosystems, Foster City, CA, 
USA). The following thermal cycling conditions were used: 48°C 
for 30 min, 95°C for 10 min, 40 cycles of 95°C for 15 s followed 
by 60°C for 60  s. Each sample was analyzed in triplicate and 
mean cycle threshold values (Ct) were used for further analysis. 
Ct values were normalized for GAPDH expression levels and 
normalized to control samples. Relative quantification values 
were calculated as 2−δδCt.
cell Proliferation assay
Antiproliferative effect of AVP analogs was measured on rapidly 
growing tumor cells using MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; Sigma-Aldrich, St. Louis, 
MO, USA) or MTS assay [3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; 
Promega, Madison, WI, USA]. Briefly, depending on tumor cell 
line, cells were plated in 96-well flat bottom plates at a density of 
3–5 × 103 cell/well in 200 µl in RPMI-1640 supplemented with 
10% FBS, allowed to attach ON, and then treated with dDAVP or 
[V4Q5]dDAVP (100–1,500 nM) or vehicle for 72 h. MTT or MTS 
reagent (20 µl) was added to each well and the plate was incubated 
at 37°C for 2–4  h. For MTT the absorbance of each well was 
measured in a microplate reader at 570 nm after solubilization 
using dimethyl sulfoxide. For MTS, absorbance was measured at 
490  nm. The optical density of control cells was considered as 
100% viability.
Doubling Time
For doubling time calculation, cells were seeded at 3 × 104 cells/
well in 12-well plate in presence or not of dDAVP 1,000  nM. 
Viable cells were counted every 24 h for 72 h using trypan blue 
dye exclusion. Doubling time was calculated during the last 
3 days of the exponential growth phase.
small interfering rna (sirna)
To study the interaction of [V4Q5]dDAVP with V2r, we inter-
fered the expression of the molecule. The sequences of siRNA 
for the sense and antisense strands were: for anti-V2r siRNA, 
sense 5′-GAGGAUGACGCUAGUGAUUTT-3′ and antisense 
3′-TTCUCCUACUGCGAUCACUAA-5′; for control siRNA, 
sense 5′-CAGUCAGGAGGAUCCAAAGTT-3′ and antisense 
3′-TTGUCAGUCCUCCUAGGUUUC-5′ (36). Synthetic oligo-
nucleotides (Thermo Fisher Scientific Inc., USA) were annealed 
to form a short double-stranded RNA with a 3′-dithymidine 
overhang. On day 0, NCI-H82 and NCI-H125 cells were plated 
on 60 mm dishes, grown until approximately 50–60% confluency 
and then transfected with V2r siRNA or control siRNA using 
Lipofectamine 2000 (Thermo Fisher Scientific Inc., USA), follow-
ing manufacturer’s instructions. After 4 days, cells were submitted 
to a second round of transfection under the same conditions. On 
day 3, 7.5 × 103 cells were plated in 96-well plates and then treated 
with different concentrations of [V4Q5]dDAVP for 72 h.
clonogenic assay
Cytostatic effects of dDAVP and [V4Q5]dDAVP on tumor cells 
were also examined at low-density cultures by the colony forma-
tion assay. 300 PC-3 cells/well were grown in complete medium 
in the presence of dDAVP or [V4Q5]dDAVP (100–1,500  nM). 
Complete medium with peptidic compounds was renewed after 
72 h. Seven days after cell seeding, colonies of more than 30 cells 
were counted.
Migration Transwell® assay
After on starvation, 3 × 105 NCI-H82 cells or 3 × 103 NCI-H125 
cells were seeded into the Transwell® inserts with 8 µm pore in 
24-transwell cell culture dishes (Corning, NY, USA) in serum-
free medium. The lower chamber was filled with medium con-
taining 10% FBS as chemoattractant. After 24 h incubation with 
dDAVP or [V4Q5]dDAVP at a final concentration of 1,000 nM, 
stationary cells were removed from the upper surface of the 
membranes with a cotton swab. Cells that migrated to the lower 
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surface were fixed and stained with crystal violet. Migrating cells 
in five randomly selected fields were counted and normalized to 
control.
Wound healing Migration assay
Cell migration was measured using an in  vitro wound healing 
assay as described by Segatori et al. (37). Briefly, “scratch” wounds 
were created by scraping confluent PC-3 monolayers with a sterile 
pipette tip. After 16 h incubation in RPMI 1640 supplemented 
with 10% FBS in the presence or absence of dDAVP or [V4Q5]
dDAVP at a final concentration of 1,000 nM, cells were fixed and 
stained. Ten random micrographs per well were obtained and 
migration area was quantified using Image J. software (https://
imagej.nih.gov/ij/). Wound-closure measurements were normal-
ized to the maximum “scratch” area.
Mice
Specific pathogen-free 8-week-old male athymic N:NIH(S)-nu 
mice were purchased from UNLP (Universidad Nacional de La 
Plata, Buenos Aires, Argentina) and kept, five to eight mice per 
cage, in our animal house facility at the National University of 
Quilmes. Food and water were provided ad libitum, and general 
health status of the animals was monitored daily. All protocols 
were approved by the National University of Quilmes institutional 
Animal Care Committee.
Tumor Progression
To generate lung cancer xenografts, 1 ×  105 NCI-H82 cells in 
300  µl containing serum-free RPMI-1640 and Matrigel® (1:1 
volume ratio) were injected subcutaneously in athymic mice. 
Tumor growth was measured daily with a caliper and tumor vol-
ume was calculated with the formula: 0.52 × width 2 × length. 
Tumor growth rates were also determined. Treatment started 
the cell inoculation day. A clinically relevant dose of dDAVP 
or [V4Q5]dDAVP (0.3 µg kg−1) was administered intravenously 
thrice a week (38). Animals in control group received saline 
vehicle. When control group reached a mean tumor volume 
of 1,300  mm3, animals from all experimental groups were 
sacrificed.
statistical analysis
Statistical significance was evaluated using Prism 6 statistical 
software (GraphPad, Inc., CA, USA). Results presented in this 
study are expressed as mean values ± SEM, mean values ± SD, 
or mean  ±  confidence interval (CI). The normal distribution 
of data was confirmed using the Shapiro–Wilk normality test 
and the homoscedasticity was determined with Bartlett’s test. 
For multiple comparisons between experimental groups one-
way ANOVA (followed by Dunnett or Tukey posteriori test) or 
two-way ANOVA (followed by mean 95% CI comparison test) 
were performed. For repeated measures ANOVA, the Geisser–
Greenhouse correction was used for assumption of sphericity.
Doubling time was calculated using the exponential growth 
equations and the fits were compared. Growth rates represent the 
slopes of the linear regression of the tumors volumes from day 17 
to 25. Data correspond of at least three independent experiments. 
Significant levels were defined as p < 0.05.
resUlTs
expression of V2r in lung and  
Prostate cells
In order to confirm the expression of V2r in tumor cells, an immu-
nofluorescence assay was conducted. As shown in Figure  1A, 
NCI-H82 and PC-3- cells express the V2r. NCI-H125 human 
non-small lung cancer cells are negative for V2r. MDA-MB-231, 
a cell line known to display AVP membrane receptors, was used 
as a positive control of V2r expression (32).
expression of ne Markers in the  
Tumor cell Models
Chromogranin A and NSE are the most commonly employed 
markers to determine NE characteristics, both at the tissue and in 
general circulation (39). In order to determine NE differentiation, 
the expression of NE markers, CgA and NSE, was evaluated by 
qRT-PCR. As shown in Figure 1B, qRT-PCR studies demonstrate 
that SCLC NCI-H82 and hormone-independent PC-3 cells 
express NE markers.
cytostatic effect of V2r stimulation by 
dDaVP and [V4Q5]dDaVP in lung and 
Prostate cancer cells
We evaluated the cytostatic effect of the parental peptide dDAVP 
(40) and the analog [V4Q5]dDAVP on log-phase growing lung 
and prostate cancer cells. After a 72 h exposure, both peptides 
significantly reduced proliferation in NCI-H82 and PC-3 tumor 
cell cultures. Additionally, we confirmed that V2r-negative NCI-
H125 cells did not modify their proliferative behavior in response 
to these peptides (Figure 2A).
In the NCI-H82 cell line, [V4Q5]dDAVP analog showed a 
higher cytostatic effect than dDAVP, at high (1,000 nM) as well 
as low (100 nM) concentrations, reducing cell proliferation by 
up to 40% (Figure 2A). In the PC-3 cell line, both peptides have 
similar antiproliferative effects reducing tumor cell growth by 
up to 15%.
To reconfirm the cytostatic effect of dDAVP on the studied 
cell lines, we evaluated doubling time with and without treatment 
(Figure 2B). The doubling time without treatment was 33 and 
36  h in NCI-H82 and PC-3, respectively. DDAVP treatment 
increased the doubling time in both cell lines: 7 h in NCI-H82 
and 6 h in PC-3. The comparison of fits was significate in both 
lines (NCI-H82 control cells doubling time: 33  h, R  =  0.98; 
NCI-H82 dDAVP treatment cells doubling time: 40 h, R = 0.96; 
PC-3 control cells doubling time: 36 h, R = 0.92; PC-3 dDAVP 
treatment cells doubling time: 42 h, R = 0.93).
In order to complement high density proliferation assays, 
we studied the peptide ability to modify in vitro low density cell 
growth using a clonogenic growth assay (41).
Incubation with dDAVP and [V4Q5]dDAVP (100–1,500 nM) 
during 1 week significantly reduced the number of PC-3 tumor 
cell colonies showing a higher effect than the observed in prolifer-
ation assays using log-phase growing cells, inhibiting clonogenic 
growth by up to 30 or 40%, respectively (Figure 3).
FigUre 1 | expression of V2r by immunofluorescence detection and of neuroendocrine (ne) markers by quantitative rT-Pcr (qrT-Pcr).  
(a) V2r expression was detected using a specific anti-V2r antibody and a secondary antibody labeled with FITC-conjugated goat anti-rabbit IgG. Nuclei were labeled 
with DAPI. Negative controls consisted of omission of the primary antibody and were consistently negative (Insets). NCI-H82 human small cell lung cancer cells and 
PC-3 human prostate cancer cells expressed the V2r. NCI-H125 human nSCLC cells were negative for the receptor. MDA-MB-231 human breast carcinoma cells 
were used as a positive control (original magnification ×1,000). (B) For expression of NE markers, chromogranin A and specific neuronal enolase expression levels 
were evaluated by qRT-PCR in NCI-H82 and PC-3 cells. Each sample was analyzed in triplicate and mean cycle threshold values (Ct) were used for further analysis. 
Ct values were normalized for GAPDH expression levels and expressed in relation to control samples (NCI-H125). Relative quantification values were calculated as 
2−ΔΔCt. Results are expressed as mean ± SEM.
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silencing of V2r on Tumor cell lines
Additionally, to determined that [V4Q5]dDAVP acts by V2r, we 
interfered the expression of the molecule. V2r was depleted using 
siRNA on NCI-H82 and NCI-H125 cells. The silencing of V2r 
significantly attenuated the inhibitory effects of [V4Q5]dDAVP on 
cell proliferation compared to control siRNA-transfected NCI-
H82 cells. The silencing had no effect on NCI-H125 (Figure 4), 
indicating that antiproliferative effect mainly results from V2r 
activation.
effect of dDaVP and [V4Q5]dDaVP  
on Tumor cell Motility
In vitro treatment at 1,000  nM concentration of both studied 
peptidic analogs decreased tumor cell migration by 60–70% 
in NCI-H82 (Figure 5A) and 30–40% in PC3 (Figures 5C,D), 
tumor cells using Transwell® and wound assays, respectively. 
DDAVP and [V4Q5]dDAVP did not affect migratory capacity of 
V2r-negative NCI-H125 cells (Figure 5B).
regulation of ne Markers in  
Tumor cells by dDaVP Treatment
As previously shown, NCI-H82 and PC-3 cells express high 
levels of NE markers with clinical relevance. In order to evaluate 
if dDAVP by V2r has the capacity of modulating NE markers 
level expression, transcript levels in tumor cells were measures 
by qRT-PCR after ON incubation with 1,000 nM of dDAVP. As 
shown in Figure 6, the expression of NE markers was dramati-
cally reduced after treatment by 90% for NSE and 80% for CgA 
FigUre 2 | antiproliferative effects of vasopressin analogs on lung and prostate cancer cells. Effect of desmopressin (dDAVP) and [V4Q5]dDAVP 
(100–1,000 nM) on log-phase growing cells was measured using the MTS or MTT assays. The optical density of control cells was considered as 100% viability. 
(a) Effect of dDAVP and [V4Q5]dDAVP (100–1,500 nM) on NCI-H82, PC-3, and NCI-H125 cells. Results are expressed as mean ± 95% confidence interval (CI). 
Two-way ANOVA followed by mean 95% CI comparison post hoc. *p < 0.05; **p < 0.01 (corresponding to each analog concentration vs. its control) #p < 0.05 
(dDAVP concentration vs. same [V4Q5]dDAVP concentration). For doubling time calculation; viable cells were counted every 24 h for 72 h using trypan blue dye 
exclusion. Doubling time with and without dDAVP 1,000 nM treatment was calculated with the exponential phase of growth, control and treatment curves fit at 72 h 
were compared on each cell line. (B) Doubling time of NCI-H82 and PC-3 cells. Results are expressed as mean ± SEM of cells number at 72 h. Comparison of fits 
**p < 0.001.
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on NCI-H82 cells and by 80% for NSE and 95% for CgA on PC-3 
cells (Figure 6).
effect of dDaVP and [V4Q5]dDaVP on 
Xenograft Tumor Progression
Finally, we explored the effect of dDAVP and [V4Q5]dDAVP in 
NCI-H82 xenograft growth in nude mice. Briefly, mice received 
thrice a week intravenous doses of the analogs (0.3 µg kg−1) after 
tumor confirmation by palpation. Treatment for 25  days with 
both peptide analogs significantly reduced final tumor volume by 
40% in comparison vehicle-treated group (Figures 7A,B). Tumor 
growth rates (from day 17 to 25) were also reduced by about 
35% after dDAVP or [V4Q5]dDAVP treatment (rates growth: 
control:132.4  ±  14.64; dDAVP: 86.8  ±  8.37; [V4Q5]dDAVP: 
86.54 ± 11.73). Rates growth expressed as slope ± SD.
DiscUssiOn
The participation of neuropeptides in tumor growth, particularly 
in NETs, has always been object of study with the aim of dis-
covering mechanisms involved in cancer progression and new 
therapeutic targets. NETs are a heterogeneous group of tumors 
with different characteristics. These tumors are, generally, aggres-
sive and resistant to current therapies. Although NETs are rare, 
these have been increasing in incidence. Symptoms are often 
non-specific and do not necessarily lead to the identification of 
the specific lend themselves to identifying the specific underlying 
tumor. The NETs cells were characterized by the expression of 
markers such as neuropeptides. These circulating markers from 
specific tumor types can be used for diagnostic and prognostic 
information of NETs (40). The expression of AVP receptors on 
several types of tumors like SCLC and breast cancer highlights the 
multifaceted role of AVP, such as predicted by North et al. (17–20). 
Additionally, it was recently reported that different AVP recep-
tors are expressed throughout the gastrointestinal tract tumors, 
including colon and pancreas, with interesting pathophysiologi-
cal implications (14, 15). Unlike V1ar and V1br, V2r is associated 
with antiproliferative signaling, involving activation of adenylate 
cyclase followed by intracellular cAMP elevation (41). Increases in 
cAMP levels using cAMP analogs or cAMP elevating agents such 
as forskolin or different hormone derivatives can trigger cell cycle 
arrest at G1 phase and induce apoptosis in numerous cancer cell 
types, suppressing tumor growth. These antiproliferative effects 
are mediated by PKA and correlated with the increase of cell cycle 
inhibitor p27kip1 and the decrease of antiapopotic bcl2 protein 
FigUre 3 | effect of vasopressin analogs on clonogenic growth of 
Pc-3 cells. (a) Effect of desmopressin or [V4Q5]dDAVP treatment on 
clonogenic growth of PC-3 cells. Cells were seeded in 96-well plates and 
incubated with varying concentrations of compounds (100–1,500 nM) in 
complete medium for 7 days. Results are expressed as mean ± confidence 
interval 95%. Two-way ANOVA proved not significant for the interaction and 
the factor “analog” and significant for the factor “concentration.” Dunnett 
post hoc test corresponding to each analog concentration vs. its control; 
*p < 0.05; **p < 0.01. (B) Representative photographs of PC-3 colonies at 
different concentrations (original magnification ×40).
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levels in MDA-MB-231 cells. Proliferative signal transmission 
through the Ras/Raf/ERK pathway is blocked by the elevation 
of cellular cAMP levels mainly via PKA-mediated Raf inhibition 
(42, 43). We have demonstrated that the treatment with [V4Q5]
dDAVP resulted in partial arrest of MDA-MB-231 cells in G0/G1 
phase (32), further studies on apoptosis are needed.
Because stimulation of this pathway can trigger deleterious 
effects on cancer cells (23), compound like dDAVP which specifi-
cally activate V2r, have a potential role as anticancer agents (44, 
45). dDAVP has demonstrated to display antitumor properties 
in breast and colorectal cancer, showing an angiostatic and anti-
metastatic effect, disrupting cooperative interactions of tumor 
and endothelial cells during tumor progression (28, 30).
[V4Q5]dDAVP was selected from a panel of peptidic analogs 
derivatized from dDAVP with different structural modifications 
(31). Novel compound [V4Q5]dDAVP exhibited a significantly 
higher cytostatic, angiostatic, and antimetastatic effects against 
breast cancer cells than the parental compound (32, 33).
In this work, we examined the impact of selective stimula-
tion of V2r on key cellular events related to tumor progression 
through the use of the two analogs V2r agonists, dDAVP and 
[V4Q5]dDAVP, of the neuropeptide AVP, on lung and prostate 
tumor lines with NE phenotypes. NCI-H82 and PC-3 cancer 
cells are highly aggressive human cell lines which, as we show 
in the present study, express high levels of NE markers NSE 
and CgA as well as the AVP receptor V2. DDAVP and [V4Q5]
dDAVP significantly reduced proliferation, doubling time, and 
migration in both tumor cell cultures. [V4Q5]dDAVP analog 
showed a higher cytostatic effect than dDAVP, both at low and 
high concentrations, obtaining a maximum inhibition of 40% on 
cellular proliferation in the NCI-H82 cell line. As early exposed, 
activation of V2r signaling involves an increase in cAMP levels. It 
has been described that stimulation of cAMP/PKA pathway result 
in inhibition of cell migration in different cancer cell (46,  47). 
In lung cancer cells, migration inhibition was also greater with 
[V4Q5]dDAVP than with parental peptide reducing cell motility 
by 64 and 50%, respectively, although this difference was not 
statistically significant.
Antitumor profile of dDAVP on PC-3 cells was similar to 
that obtained in a study by Sasaki et al., where they reported the 
antiproliferative and anti-invasive ability of dDAVP on prostate 
cancer cells related to antiproliferative and antimigratory ability 
(48). Interestingly, [V4Q5]dDAVP was not better than dDAVP 
in the PC-3 model and this difference could be related to the 
characteristics of the cell line.
It has been reported that, under certain culture conditions, 
only some subpopulation of PC-3 cells undergo NE transdif-
ferentiation. In this highly heterogeneous cell line, it may be 
possible that only a fraction of the total cell population express 
NE markers or V2r. In the latter, inhibition of cell growth by V2r 
agonists may be subtle and differences between analogs may be 
more difficult to assess (49).
For this reason, we, additionally, studied peptides ability to 
modify in vitro low density cell growth using a clonogenic growth 
assay. This method complemented MTT assay, because the con-
ditions are most limiting, and thus, this assay is better for the 
evaluation of new anticancer agents (50). The inhibitory effect of 
both analogs was higher than the observed in proliferation assays 
using log-phase growing cells and [V4Q5]dDAVP analog showed 
a major cytostatic effect than dDAVP inhibiting up to 40% of cell 
growth at high concentrations, although this difference was not 
statistically significate.
We also showed that [V4Q5]dDAVP acts via V2r. The silencing 
of V2r significantly attenuated the inhibitory effects of [V4Q5]
dDAVP on cell proliferation. This result complements the already 
reported findings by our group, where chemical V2r blockade 
by the selective antagonist tolvaptan completely abolished [V4Q5]
dDAVP effects in MDA-MB-231 breast cancer cells (32) and, also, 
the findings by Keegan et al. (23), where the use of satavaptan 
(another non-peptidic V2r antagonist) blocked the mild cyto-
static effects of dDAVP on human breast cancer cells.
Neuroendocrine differentiation of tumors is related with 
the transition from cancer cells with epithelial features to cells 
with invasive and metastatic phenotypes (51). Interestingly, 
after dDAVP treatment, expression of both NE markers studied 
was reduced on lung and prostate cancer cell lines. In prostate 
cancer, transition from primarily androgen-dependent tumor 
FigUre 5 | effect of desmopressin (dDaVP) and [V4Q5]dDaVP on lung and prostate cancer cells migration. NCI-H82 cells or NCI-H125 cells were starved 
and were added to the top chambers of 24-well Transwell® permeable support with 8 µm pore in serum-free medium. The lower chamber was filled with medium 
containing 10% fetal bovine serum and dDAVP or [V4Q5]dDAVP at a final concentration of 1,000 nM. After incubating for 24 h, migrated cells on the bottom of the 
insert were stained with crystal violet (NCI-H125) or counted in Neubauer chamber (NCI-H82 cells). The number of migrating cells randomly selected in five fields 
was counted. Migration of PC-3 cells was measured using wound-healing assay. Wounds were created by scraping confluent PC-3 monolayers. After 16 h 
incubation in the presence or absence of dDAVP or [V4Q5]dDAVP at a final concentration of 1,000 nM, cells were fixed and stained. Wounds were quantified using 
Image J. software. Wound closure measurements were normalized to the maximum scratch area. (a) Effect of dDAVP and [V4Q5]dDAVP on Transwell® migration of 
NCI-H82. (B) Effect of dDAVP and [V4Q5]dDAVP on Transwell® migration of NCI-H125. (c) Effect of dDAVP and [V4Q5]dDAVP on wound migration of PC-3. 
(D) Representative microphotographs of PC-3 cells wound migration. Results are expressed as mean ± SEM One-way ANOVA followed by Tukey post hoc test. 
**p < 0.01; ***p < 0.001.
FigUre 4 | silencing of V2r on nci-h82 and Pc-3 cells. NCI-H82 and NCI-H125 cells were transfected with V2r small interfering RNA (siRNA) or control siRNA 
using Lipofectamine 2000. On day 7, cells were plated in 96-well plates and then treated with different concentrations (100–1,500 nM) of [V4Q5]dDAVP for 72 h. Cell 
growth was measured by colorimetric MTT or MTS assay. (a) Effect of [V4Q5]dDAVP on V2r silenced NCI-H82 cells. (B) Effect of [V4Q5]dDAVP on V2r silenced 
NCI-H125 cells. Results are expressed as mean ± confidence interval 95%. Two-way ANOVA followed by mean 95% confidence interval comparison post hoc 
**p < 0.01.
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FigUre 6 | Modulation of neuroendocrine markers in lung and prostate cancer cells by desmopressin (dDaVP) treatment. The relative mRNA 
expression of specific neuronal enolase (NSE) and chromogranin A (CgA) was evaluated by quantitative RT-PCR in NCI-H82 and PC-3 cells incubated with 
1,000 nM of dDAVP as described in the Figure 1. Quantification relative CgA and NSE in (a) NCI H82 cells and (B) PC-3 cells.
FigUre 7 | effect of treatment of desmopressin (dDaVP) and [V4Q5]
dDaVP on tumor growth of lung cancer xenografts. (a) NCI-H82 tumor 
volume in mice receiving saline vehicle (control) or 0.3 μg kg−1 of dDAVP or 
[V4Q5]dDAVP over time. To generate lung cancer xenografts, NCI-H82 cells 
and Matrigel® were injected subcutaneously in athymic mice. Tumors were 
measured daily with a caliper and tumor volume was calculated. dDAVP or 
[V4Q5]dDAVP were administered intravenously thrice a week. When the 
control group reached a mean tumor volume of 1,300 mm3, animals were 
sacrificed. Results are expressed as mean ± SEM Repeated measures 
ANOVA test followed by Tukey post hoc test ***p < 0.001. (B) Comparison of 
tumor volume at day 25. Results are expressed as mean ± SD. One-way 
ANOVA followed by Dunnett post (**p < 0.01; ***p < 0.001).
toward a hormone-independent tumor represents an unfavorable 
prognosis. NE transdifferentiation is fundamental in this process 
and contributes to tumor progression and hormone resistance 
(52,  53). Additionally, in lung cancer, transformation from 
nSCLC to SCLC was associated with poor treatment response and 
rise of NSE in serum (8, 54). A reduction of the expression of NE 
markers could indicate NE dedifferentiation. In cancer patients, 
elevated CgA and NSE levels correlates with tumor burden, num-
ber of dissemination sites, and lack of clinical response, while a 
decrease of these biomarkers might indicate a better prognosis 
(55). dDAVP capacity to modulate NE markers in different tumor 
types constitutes an interesting and important contribution for 
further studies.
Finally, we explored the in vivo effect of dDAVP and [V4Q5]
dDAVP on NCI-H82 SCLC xenografts. Intravenous injection of 
clinically relevant doses of both analogs provoked an important 
reduction of subcutaneous tumor volume compared to control 
group. According to the in vitro effect observed, treated tumors 
grew at a 35% slower rate in comparison to vehicle-treated ani-
mals. In these experimental conditions, [V4Q5]dDAVP analog did 
not show a higher effect than the parental peptide dDAVP. [V4Q5]
dDAVP analog has displayed a more potent activity in  vivo in 
several models of breast cancer compared to parental drug. There 
is a probability that aggressive tumors as SCLC with an extremely 
fast expansion and rate of growth demand a higher dose to show 
differences between compounds. These results are preliminaries 
and require further studies in vivo, mainly, of dose evaluation to 
conclude.
NCI-H82 represents a valuable disease model of recurrent and 
drug-resistant NE SCLC (8). This is the first time that the efficacy 
of these synthetic analogs of AVP as antitumor agents on SCLC 
is demonstrated. Nowadays, targeted therapies like interferon, 
SSA, and VEGF and mTOR inhibitors became an integral part 
of therapies for NE tumors, particularly for well-differentiated 
and slow-growing gastroenteropancreatic tumors while chemo-
therapy is reserved for poorly differentiated and progressive 
tumors. Successful treatment of disseminated NETs requires a 
multimodal approach where radical tumor surgery may be cura-
tive but is rarely possible (56).
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